The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Research Report 2025
Synopsis
Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.
The global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market was valued at US$ 5107.4 million in 2023 and is anticipated to reach US$ 6449.9 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs.
Report Scope
The Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Active Biotech Ab
Amgen
Bayer AG
Cipla Limited
Roche Holding AG
Glaxosmithkline Plc
Novartis Ag
Pfizer, Inc.
Segment by Type
Afinitor (Everolimus)
Avastin (Bevacizumab)
Cabomety (Cabozantinib)
Inlyta (Axitinib)
Nexavar (Sorafenib)
Proleukin (Aldesleukin)
Torisel (Temsirolimus)
Sutent (Sunitinib)
Votrient (Pazopanib)
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.
The global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market was valued at US$ 5107.4 million in 2023 and is anticipated to reach US$ 6449.9 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs.
Report Scope
The Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Active Biotech Ab
Amgen
Bayer AG
Cipla Limited
Roche Holding AG
Glaxosmithkline Plc
Novartis Ag
Pfizer, Inc.
Segment by Type
Afinitor (Everolimus)
Avastin (Bevacizumab)
Cabomety (Cabozantinib)
Inlyta (Axitinib)
Nexavar (Sorafenib)
Proleukin (Aldesleukin)
Torisel (Temsirolimus)
Sutent (Sunitinib)
Votrient (Pazopanib)
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Afinitor (Everolimus)
1.2.3 Avastin (Bevacizumab)
1.2.4 Cabomety (Cabozantinib)
1.2.5 Inlyta (Axitinib)
1.2.6 Nexavar (Sorafenib)
1.2.7 Proleukin (Aldesleukin)
1.2.8 Torisel (Temsirolimus)
1.2.9 Sutent (Sunitinib)
1.2.10 Votrient (Pazopanib)
1.3 Market by Application
1.3.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Perspective (2019-2030)
2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Growth Trends by Region
2.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Region (2019-2024)
2.2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Region (2025-2030)
2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Dynamics
2.3.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Industry Trends
2.3.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers
2.3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Challenges
2.3.4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue
3.1.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue (2019-2024)
3.1.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue
3.4 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio
3.4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2023
3.5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players Head office and Area Served
3.6 Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
3.7 Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Type
4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Type (2019-2024)
4.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2025-2030)
5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Application
5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Application (2019-2024)
5.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
6.2 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
6.4 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
7.2 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
7.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
8.2 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
9.2 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
9.4 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
10.2 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Active Biotech Ab
11.1.1 Active Biotech Ab Company Detail
11.1.2 Active Biotech Ab Business Overview
11.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.1.4 Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.1.5 Active Biotech Ab Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.2.4 Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Bayer AG
11.3.1 Bayer AG Company Detail
11.3.2 Bayer AG Business Overview
11.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.3.4 Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.3.5 Bayer AG Recent Development
11.4 Cipla Limited
11.4.1 Cipla Limited Company Detail
11.4.2 Cipla Limited Business Overview
11.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.4.4 Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.4.5 Cipla Limited Recent Development
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Detail
11.5.2 Roche Holding AG Business Overview
11.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.5.4 Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.5.5 Roche Holding AG Recent Development
11.6 Glaxosmithkline Plc
11.6.1 Glaxosmithkline Plc Company Detail
11.6.2 Glaxosmithkline Plc Business Overview
11.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.6.4 Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.6.5 Glaxosmithkline Plc Recent Development
11.7 Novartis Ag
11.7.1 Novartis Ag Company Detail
11.7.2 Novartis Ag Business Overview
11.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.7.4 Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.7.5 Novartis Ag Recent Development
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Detail
11.8.2 Pfizer, Inc. Business Overview
11.8.3 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.8.4 Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.8.5 Pfizer, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
